´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢[email protected]
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢[email protected]
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.
Home > ÀüÁ¦Ç°º¸±â > Gene transfer (virus) > Lentivirus > Lenti-X¢â SARS-CoV-2 Packaging Mix
SARS-CoV-2-pseudotyped lentivirus »ý»ê

Lenti-X¢â SARS-CoV-2 Packaging Mix

-

Á¦Á¶»ç Á¦Ç°ÄÚµå Á¦Ç°¸í ¿ë·® °¡°Ý
(ºÎ°¡¼¼º°µµ)
ºñ°í »ç¿ëÀڸŴº¾ó
Clontech
632668
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (WT Spike, Full Length)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
(Package)
1,663,200¿ø 
2,079,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
632669
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (D614G Spike, Full Length)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
(Package)
1,663,200¿ø 
2,079,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
632670
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (WT Spike, Truncated)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
(Package)
1,663,200¿ø 
2,079,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
632671
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (D614G Spike, Truncated)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
(Package)
1,663,200¿ø 
2,079,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
631292
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (B.1.351 Spike, Full Length)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
(Package)
1,692,000¿ø 
2,115,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
x253498
Clontech
631293
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (B.1.351 Spike, Truncated)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
(Package)
1,692,000¿ø 
2,115,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
x253498
Clontech
632672
Lenti-X¢â SARS-CoV-2 Packaging Mix (WT Spike, Full Length)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
1,336,000¿ø 
1,670,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
632673
Lenti-X¢â SARS-CoV-2 Packaging Mix (D614G Spike, Full Length)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
1,336,000¿ø 
1,670,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
632674
Lenti-X¢â SARS-CoV-2 Packaging Mix (WT Spike, Truncated)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
1,336,000¿ø 
1,670,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
632675
Lenti-X¢â SARS-CoV-2 Packaging Mix (D614G Spike, Truncated)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
1,336,000¿ø 
1,670,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
631295
Lenti-X¢â SARS-CoV-2 Packaging Single Shots (Universal)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
16 ȸ
(Package)
2,015,200¿ø 
2,519,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots (Universal) Protocol-at-a-Glance.pdf
Clontech
631290
Lenti-X¢â SARS-CoV-2 Packaging Mix (B.1.351 Spike, Full Length)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
1,364,800¿ø 
1,706,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
x253498
Clontech
631291
Lenti-X¢â SARS-CoV-2 Packaging Mix (B.1.351 Spike, Truncated)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
12 ȸ
1,364,800¿ø 
1,706,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
x253498
Clontech
632676
Lenti-X¢â SARS-CoV-2 Packaging Mix (No-Envelope Control)
°ü·ÃÇмú ±¸¸ÅÇϱ⠶óÀ̼±½º 
6 ȸ
249,600¿ø 
312,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-At-A-Glance.pdf
Clontech
631289
Human ACE2 293T Cell Line
°ü·ÃÇмú ±¸¸ÅÇϱâ LMOÁ¦Ç°  ¶óÀ̼±½º 
1 §¢
3,186,400¿ø 
3,983,000¿ø
°¡°ÝÇÒÀÎ
11.01 ~ 12.27
Á¦Á¶»ç ÆäÀÌÁö·Î ¹Ù·Î°¡±â
x254731

* º» Á¦Ç°Àº Biosafety Level 2 ÀÌ»óÀÇ ½Ã¼³¿¡¼­ »ç¿ë °¡´ÉÇÕ´Ï´Ù.

  • ³ôÀº ¿ª°¡ÀÇ ¹ÙÀÌ·¯½º »ý»êÀ» À§ÇÑ ÃÖÀûÀÇ Á¶ÇÕ
    - ½ÇÇè ÃÖÀûÈ­¸¦ À§ÇÑ ½Ã°£/½Ã¾à ¼Ò¸ð ºÒÇÊ¿ä
  • Æí¸®ÇÑ Single shot ÇüÅ·Î, hands-on timeÀ» ÃÖ¼ÒÈ­ÇÏ°í, error ¹æÁö
    - Single Shot¿¡ ¼±ÅÃÇÑ transfer reporter vector (ZsGreen1 ¹ßÇö/luciferase ¹ßÇö)¿Í D.W.¸¦ ÷°¡ÇÏ¿© packaging cell¿¡ ó¸®ÇÏ´Â °Í ¸¸À¸·Î packaging ¿Ï·á
  • SARS-CoV-2 spike protein variant¿¡ µû¸¥ Á¦Ç° ¼±ÅÃ
    -> WT (full length) - Wuhan-Hu-1 (NC_045512.2)·ÎºÎÅÍ À¯·¡ÇÑ SARS-CoV-2 ¼­¿­À» ÀÌ¿ëÇßÀ¸¸ç, mammalian cell¿¡¼­ ¹ßÇöµÉ ¼ö ÀÖµµ·Ï ÃÖÀûÈ­.
    -> D614G (full length) - ÇöÀç À¯ÇàÇÏ´Â ´ëºÎºÐÀÇ ¹ÙÀÌ·¯½º¿¡¼­ º¸ÀÌ´Â D614G mutation spike protein coding sequence Æ÷ÇÔ (Isabel et al. 2020).
    -> B.1.351 (full length) - South Africa·ÎºÎÅÍ À¯·¡µÈ °ÍÀ¸·Î È®ÀεǴ B.1.351 mutation spike protein coding sequence Æ÷ÇÔ (Johnson et al. 2020).
    -> WT (truncated) / D614G (truncated) / B.1.351 (truncated) - WT spike¿Í D614G, B.1.351 spike coding sequence¿¡¼­ C-terminiÀÇ ER retention signalÀ» Á¦°ÅÇÏ¿© ¹ÙÀÌ·¯½º°¡ ¹ßÇöÇÏ´Â spike proteinÀÌ Áõ°¡ÇÏ°í, ³ôÀº °¨¿°·Â È®ÀÎ (Johnson et al. 2020)
  • Envelope°ú SARS-CoV-2 spike protein variant¸¦ Á÷Á¢ customÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖ´Â universal typeÀÇ Á¦Ç° Á¦°ø
    - D614G / B.1.1.7 / B.1.351 truncated vector 3Á¾ÀÌ ¸ðµÎ ±¸¼ºÇ°À¸·Î Á¦°øµÊ
    - ¿øÇÏ´Â envelopeÀ» Á÷Á¢ cloningÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖ´Â pEmpty vector°¡ Æ÷ÇԵǾî ÀÖÀ½
  • Neutralization assay¸¦ À§ÇÑ no-envelope control Á¦°ø
  • Human ACE2 À¯ÀüÀÚ¸¦ ³ô°Ô ¹ßÇöÇÏ´Â 293T cell line
    - ¹ÙÀÌ·¯½º¿Í receptor°£ÀÇ »óÈ£ÀÛ¿ëÀ̳ª ¹ÙÀÌ·¯½º °¨¿° °æ·Î µî È®ÀÎ
Cell Line Ãë±Þ ÁÖÀÇ»çÇ× (Ŭ¸¯)
Á¦Ç°¼³¸í
[Lenti-X¢â SARS-CoV-2 Packaging Single Shots]
COVID-19 Ä¡·áÁ¦ °³¹ßÀ» À§Çؼ­´Â SARS-CoV-2 °¨¿°ÀÌ ¾ïÁ¦µÇ´ÂÁö¸¦ ÀÔÁõÇÏ´Â °ÍÀÌ ÇÊ¿äÇÏ´Ù. ÀÌ °úÁ¤¿¡¼­ SARS-CoV-2¸¦ Á÷Á¢ »ç¿ëÇϱâ À§Çؼ­´Â ¾ÈÀü Á¶Ä¡ µîÀÌ ¿ä±¸µÇ±â ¶§¹®¿¡, ¿¬±¸ÀÚµéÀº SARS-CoV-2 spike protein (Ni et al. 2020, Shang et al. 2020)À» °¡Áö´Â pseudotypeÀÇ ´ëü ¹ÙÀÌ·¯½º¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ´Ù.
Lenti-X¢â SARS-CoV-2 Packaging Single Shots¸¦ ÀÌ¿ëÇϸé, ´ÙÄ«¶ó¹ÙÀÌ¿ÀÀÇ Lentivirus packaging ±â¼úÀ» Àû¿ëÇÏ¿© SARS-CoV-2 spike-pseudotypedÀ» °¡Áö´Â °í¿ª°¡ Lentivirus¸¦ ¼Õ½±°Ô »ý»êÇÒ ¼ö ÀÖ´Ù.

[Human ACE2 293T Cell Line]
Lenti-X SARS-CoV-2 Packaging Single ShotsÀ¸·Î »ý»êµÈ ¹ÙÀÌ·¯½º´Â Human ACE2 293T Cell Line¿¡ transductionÇÏ¿© ¹ÙÀÌ·¯½º °¨¿° °æ·Î³ª receptor °£ÀÇ »óÈ£ÀÛ¿ë, neutralization assay¿¡ È¿À²ÀûÀ¸·Î »ç¿ëµÉ ¼ö ÀÖÀ¸¸ç, Ä¡·áÁ¦ °³¹ß¿¡µµ È°¿ëÇÒ ¼ö ÀÖ´Ù.
Human ACE2 293T cell lineÀº HEK cell line¿¡ Lentivirus¸¦ ÀÌ¿ëÇØ ACE2À¯ÀüÀÚ¸¦ µµÀÔÇÏ¿´À¸¸ç, ¿©·¯ Â÷·ÊÀÇ °è´ë ¹è¾ç¿¡µµ ACE2 À¯ÀüÀÚ ¹ßÇöÀÌ À¯ÁöµÊÀ» RT-qPCR·Î È®ÀÎÇÏ¿´´Ù.
ACE2´Â ¾Æ¿¬À» Æ÷ÇÔÇÑ metalloenzyme (Zinc-containing metalloenzyme)À¸·Î½á, ³»Çdzª ¿©·¯ ¼¼Æ÷ Ç¥¸é¿¡ À§Ä¡ÇÑ transmembrane proteinÀÌ´Ù. ÀÌ ´Ü¹éÁúÀº ½É±Ù¼¼Æ÷¿¡¼­ hypertrophic effect¸¦ º¸ÀÌ´Â angiotensin IÀ» angiotensin 1-9·Î, 9-amino acid peptide¿Í angiotensin II¸¦ angiotensin 1-7·Î ÀüȯÇÔÀ¸·Î½á, ÀÎü¿¡ À¯ÀÍÇÑ Ç÷°ü È®ÀåÀ̳ª Áõ½Ä ¾ïÁ¦ ¹°Áú·Î ÀÛ¿ëÇÏ°Ô ÇÑ´Ù.
Streamlined, one-step workflow
Lenti-X¢â SARS-CoV-2 Packaging Single ShotsÀº Xfect¢â transfection ½Ã¾à°ú Lentiviral packaging plasmid°¡ ÃÖÀûÀÇ ºñÀ²·Î È¥ÇÕµÇ¾î µ¿°á°ÇÁ¶ ÇüÅ·ΠÁ¦°øµÈ´Ù. ¾ò°íÀÚ ÇÏ´Â ¹ÙÀÌ·¯½ºÀÇ spike protein variant¸¦ Æ÷ÇÔÇÏ´Â single shotÀ» ¼±ÅÃÇÒ ¼ö ÀÖ°í, ¹ÙÀÌ·¯½º µµÀÔ È¿À² È®ÀÎÀ» À§ÇÑ reporter°¡ »ðÀԵǾî ÀÖ´Â transfer vector (ZsGreen1 ȤÀº luciferase)¿Í D.W¸¦ single shot°ú ¼¯¾î packaging cell (e.g. Lenti-X¢â 293T Cell Line)¿¡ ³Ö´Â °Í ¸¸À¸·Î packagingÀÌ ¿Ï·áµÈ´Ù. Transfection ÈÄ 48-72½Ã°£ ÈÄ¿¡ »óÃþ¾×¿¡¼­ ¹ÙÀÌ·¯½º¸¦ ȸ¼öÇÒ ¼ö ÀÖ´Ù.
Á¦Ç° ¼º´É È®ÀÎ

±×¸² 1. ACE2-positive cell¿¡¼­ÀÇ SARS-CoV-2 pseudovirus µµÀÔ È¿À² È®ÀÎ
Human ACE2 receptor¸¦ ¾ÈÁ¤ÀûÀ¸·Î ¹ßÇöÇÏ´Â HEK293T cell¿¡ SARS-CoV-2 pseudovirus¸¦ µµÀÔÇÑ ÈÄ, ZsGreen1À» ÀÌ¿ëÇØ °¢ spike protein º° µµÀÔ È¿À²À» ºñ±³ÇÏ¿´´Ù.

(Panel A) WT spike¿Í D614G spikeÀÇ type º° transduction efficiency ºñ±³
Lenti-X SARS-CoV-2 Packaging Single Shots were used to generate lentiviral particles pseudotyped with either WT (Wuhan-Hu-1) or D614G variants of the spike protein, and encoding the fluorescent protein ZsGreen1. 100 ¥ìl of supernatant from each prep was used to transduce an HEK293T cell line stably expressing the human ACE2 receptor in the presence of 6 ¥ìg/ml polybrene in 48-well plates. Transduction efficiencies for each sample were measured by flow cytometry 6 days posttransduction.
(Panel B) B.1.351 spike¿Í D614G spikeÀÇ type º° transduction efficiency ºñ±³
Lenti-X SARS-CoV-2 Packaging Single Shots (B.1.351 or D614G spike, full length or truncated) were used to produce pseudovirus encoding the fluorescent protein ZsGreen1. Viral particles were concentrated 50-fold (B.1.351 full length) or 20-fold (B.1.351 truncated and D614G) using Lenti-X Concentrator following the standard protocol, and different volumes of each prep were used to transduce a HEK293T cell line stably expressing the human ACE2 receptor in the presence of 6 ¥ìg/ml polybrene in 48-well plates. Transduction efficiencies for each sample were measured by flow cytometry 6 days posttransduction


±×¸² 2. ACE2-positive cell¿¡¼­ÀÇ SARS-CoV-2 pseudovirus µµÀÔ È¿À² È®ÀÎ
ACE2-positive cell°ú HEK293 cell¿¡ luciferase¸¦ ¹ßÇöÇÏ´Â pseudovirus¸¦ µµÀÔÇÑ ÈÄ, °¢ ¼¼Æ÷ º°, spike protein º° È¿À²À» ºñ±³ÇÏ¿´´Ù.

(Panel A) WT spike¿Í D614G spikeÀÇ type º° transduction efficiency ºñ±³
Lenti-X SARS-CoV-2 Packaging Single Shots were used to generate lentiviral particles pseudotyped with either WT (Wuhan-Hu-1) or D614G variants of the spike protein, and pseudoviruses encoding firefly luciferase were used to transduce both the ACE2-positive cell line and an HEK293T cell line lacking ACE2 expression (included to provide a background signal for analysis of luciferase activity). Luciferase activity was measured 6 days posttransduction.

(Panel B) B.1.351 spikesÀÇ type º° transduction efficiency ºñ±³
Lenti-X SARS-CoV-2 Packaging Single Shots (B.1.351 spike, full length or truncated) were used to produce pseudovirus encoding firefly luciferase. Viral particles were concentrated 20-fold using Lenti-X Concentrator following the standard protocol, and different volumes of each prep were used to transduce an HEK293T cell line stably expressing the human ACE2 receptor in the presence of 6 ¥ìg/ml polybrene in 48-well plates. HEK293T cells lacking ACE2 expression were transduced in parallel to determine background luminescence levels, since spike-pseudotyped viruses are incapable of infecting HEK293T cells in the absence of ACE2. Luminescence values for each sample were measured 3 days posttransduction.


±×¸² 3. Lenti-X¢â SARS-CoV-2 Packaging Single Shots·Î ¾òÀº ¹ÙÀÌ·¯½ºÀÇ functional titer È®ÀÎ
(Panel A, B) Functional titers determined via analysis of ZsGreen1 reporter expression in ACE2-positive HEK293T cells transduced with SARS-CoV-2 pseudovirus (Panel A: WT spike, D614G spike / Panel B: B.1.351 spike, D614G spike)
(Panel C) Corresponding microscopy images of transduced ACE2-positive cells at 72 hours post-infection.


±×¸² 4. SARS-CoV-2 spike protein variant¿¡ µû¸¥ ACE2proteinÀÇ neutralizing activity È®ÀÎ
(Panels A, B) ACE2 HEK293T ¼¼Æ÷¿¡ SARS-CoV2 pseudovirus¿Í ACE2-Fc ´Ü¹éÁúÀ» ³óµµº°·Î ó¸®ÇÑ ÈÄ, luciferase¸¦ ÅëÇØ neutralizing activity¸¦ È®ÀÎÇÏ¿´´Ù.
Serial dilutions of soluble ACE2 protein fused to the Fc domain from IgG (ACE2-Fc) were applied, along with SARS-CoV-2 pseudovirus, to ACE2 HEK293T cells. Luciferase levels were measured 3 days post-infection as a readout for virus infectivity. Data are graphed as percent neutralization relative to virus-only control infection. Values are mean ¡¾SD and experiments were performed in triplicate.
Âü°í ¹®Çå
- Ni, L. et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 52, 971-977 (2020).
- Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 117, 11727-11734 (2020).
- Isabel, S. et al. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci Rep. 10, 14031 (2020).
- Johnson, MC. et al. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. J Virol. 94, e01062-20 (2020).
Á¦Ç° ±¸¼º
[Lenti-X¢â SARS-CoV-2 Packaging Single Shots]
±¸¼ºÇ°

¿ë·®

ºñ°í

Lenti-X SARS-CoV-2 Packaging Mix (Code 632672)

12 ȸ

º°µµ ±¸¸Å °¡´É

Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code 632676)

6 ȸ

º°µµ ±¸¸Å °¡´É

Lenti-X SARS-CoV-2 Vector Set (Code 632677)
   ±¸¼º) pLVXS-ZsGreen1-Puro Vector (Full Sequence (txt.))
   ±¸¼º) pLVXS-Luciferase-Puro Vector (Full Sequence (txt.))

2 tube

º°µµ ±¸¸Å ºÒ°¡


[Lenti-X¢â SARS-CoV-2 Packaging Single Shots (Universal)]
±¸¼ºÇ°

¿ë·®

ºñ°í

Lenti-X¢â Packaging Single Shots (Envelope-Free) (Code 631294)
   ±¸¼º) Lenti-X Packaging Single Shots (Envelope-Free)
   ±¸¼º) pEmpty Vector (Full Sequence (txt.))
   ±¸¼º) Lenti-X Reporter Vector Set

16 ȸ

º°µµ ±¸¸Å °¡´É

Lenti-X SARS-CoV-2 Spike Vector Set (Code 631296)
   ±¸¼º) 20 ¥ìl pSpike D614G Truncated Vector (500 ng/¥ìl) (Full Sequence (txt.))
   ±¸¼º) 20 ¥ìl pSpike B.1.1.7 Truncated Vector (500 ng/¥ìl) (Full Sequence (txt.))
   ±¸¼º) 20 ¥ìl pSpike B.1.351 Truncated Vector (500 ng/¥ìl) (Full Sequence (txt.))

3 tube

º°µµ ±¸¸Å ºÒ°¡





Keyword : SARS-CoV-2,COVID-19,coronavirus,Äڷγª¹ÙÀÌ·¯½º,epidemic,COVID,ÄÚºñµå,Neutralization,Neutralizing antibody,SARS-CoV-2 inhibition,pseudovirus,pseudotyped Lentivirus,vaccine,vaccine development,¹é½Å°³¹ß,¹é½Å,Ä¡·áÁ¦,Ç×ü,Ç×üġ·áÁ¦,therapeutics,monoclonal antibody therapy,BSL-2

Lentivirus
>
Lentiviral expression vector¸¦ Æ÷ÇÔÇÑ ½Ã½ºÅÛ..
CMV promoter º¤ÅÍ ½Ã½ºÅÛ
>
Á¶Ç÷¸ð¼¼Æ÷, Áٱ⼼Æ÷ µîÀÇ Lentiviral transdu..
EF1 ¥á promoter º¤ÅÍ ½Ã½ºÅÛ
>
SARS-CoV-2-pseudotyped lentivirus »ý»ê
Lenti-X¢â SARS-CoV-2 Packaging Mix
>
ÀÓ»ó Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ
3¼¼´ë Lentivirus packaging system
>
´Ù¾çÇÑ Çü±¤´Ü¹éÁú ¸®Æ÷Å͸¦ Æ÷ÇÔÇÑ Lentiviral..
Çü±¤´Ü¹éÁú ¸®Æ÷ÅÍ º¤ÅÍ
>
Tetracycline Á¸Àç ÇÏ¿¡¼­¸¸ ¸ñÀû ´Ü¹éÁúÀ» ¹ß..
Tet-on inducible Expression (Two vectors)
>
Tetracycline Á¸Àç ÇÏ¿¡¼­¸¸ ¸ñÀû ´Ü¹éÁúÀ» ¹ß..
Tet One Inducible Expression (One vector)
>
Lentivirus¸¦ ÀÌ¿ëÇÑ sgRNA, Cas9 gene deliver..
Lenti-X¢â CRISPR/Cas9 System
>
Tetracycline Á¸Àç ÇÏ¿¡¼­¸¸ ¸ñÀû ´Ü¹éÁúÀ» ¹ß..
(Legacy) Tet-Inducible expression ½Ã½ºÅÛ
>
Pormoterless vector·Î pomorter È°¼º ¿¬±¸
Reporter assay ½Ã½ºÅÛ (Promoterless vector)
>
Transfection ½Ã¾àÀ» Æ÷ÇÔÇÏ¿© ´õ °£´ÜÇÑ packa..
Packaging single shots
>
239T, HEK-293 Cellº¸´Ù ´õ ³ôÀº packaging È¿..
Packaging Cell Lines
>
1 step qRT-PCR·Î ¿ª°¡¸¦ ºü¸£°í Á¤È®ÇÏ°Ô ÃøÁ¤
Lenti-X¢â qRT-PCR Titration Kit
>
p24 ELISA·Î ºü¸£°í Á¤È®ÇÏ°Ô ¿ª°¡ ÃøÁ¤
Lenti-X¢â p24 Rapid Titer Kit (Single Wash)
>
½º¸¶Æ®ÆùÀ¸·Î 10ºÐ¸¸¿¡ Lentivirus ¿ª°¡(Titer)..
GoStix¢â Plus
>
Lentivirus ³óµµ°¡ ³·À» ¶§, Mix & SpinÀ¸·Î °£..
Lentivirus ³óÃà ½Ã¾à
>
In vivo Lentiviral delivery Àû¿ë ½Ã, ÇʼöÀû..
Lentivirus Á¤Á¦
>
Ecotropic lentivirus¸¦ human cell¿¡ Àû¿ë
Ecotropic Receptor Booster
>
Retrovirus ¹× LentivirusÀÇ transduction enha..
RetroNectin¢ç (Recombinant Human Fibronectin Fragment)
>
Lentivirus³ª MMLV retrovirusÀÇ ´õ ºü¸¥ trans..
Transduction ½Ã¾à
>
¸ñÀû ¼¼Æ÷ÀÇ À¯ÀüÀÚ¿¡ »ðÀÔµÈ Provirus copy nu..
Provirus Quantitation Kit
>
Lentivirus°¡ ¸ñÀû¼¼Æ÷ À¯ÀüÀÚ¿¡ »ðÀÔµÈ À§Ä¡¸¦..
Integration Site Analysis Kit
>
½Å°³³ä lentivirus transduction
Lenti-X¢â Transduction Sponge
>
G-Rex¢ç Bioreactor applicationÀÌ Ãß°¡µÈ, T-c..
RetroNectin¢ç Pro (Recombinant Human Fibronectin Fragment)
>
ÃÖÀûÈ­µÈ Transfection Reagent & Packaging Mi..
TransIT¢ç Lentivirus System